Cargando…

A novel Bayesian method for dual-agent Phase I dose-escalation studies using penalized D-optimality

Detalles Bibliográficos
Autor principal:	Wheeler, Graham
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981662/ http://dx.doi.org/10.1186/1745-6215-14-S1-P41

Ejemplares similares

A toxicity-dependent feasibility bound for the escalation with overdose control approach in phase I cancer trials
por: Wheeler, Graham, et al.
Publicado: (2015)

The transfer of genetically engineered lymphocytes in melanoma patients: a Phase I dose escalation study
por: Regan, Courtney, et al.
Publicado: (2015)

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
por: Wheeler, Graham M.
Publicado: (2016)

Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses
por: Heery, Christopher R, et al.
Publicado: (2015)

Preliminary results of a triple peptide escalating dose vaccination phase I/II clinical trial as consolidation treatment in women affected by ovarian cancer
por: Napoletano, Chiara, et al.
Publicado: (2013)

A product of independent beta probabilities dose escalation design for dual-agent phase I trials
por: Mander, Adrian P, et al.
Publicado: (2015)

Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer
por: Nemunaitis, John, et al.
Publicado: (2013)

PK/PD modeling supports the dose-escalation decision in VIKING
por: Lovern, M, et al.
Publicado: (2010)

A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART(®)) protein in patients with relapsed/refractory metastatic colorectal carcinoma
por: Hurwitz, Herbert, et al.
Publicado: (2014)

Innovative considerations on a phase 2a dose-finding strategy using Bayesian methods and MCP-MOD
por: Bedding, Alun, et al.
Publicado: (2015)

Addressing the barriers to implementing model based designs in dose escalation studies
por: Cornelius, Victoria, et al.
Publicado: (2015)

Some small sample properties of the EWOC design in dose escalation trials
por: Kinnersley, Nelson
Publicado: (2015)

Adaptive designs for phase II cross-over dose-finding trials using Bayesian model averaging
por: Simpson, Sarah, et al.
Publicado: (2015)

Dose Escalation Methods in Phase I Cancer Clinical Trials
por: Le Tourneau, Christophe, et al.
Publicado: (2009)

Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents
por: Le Tourneau, Christophe, et al.
Publicado: (2012)

A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer
por: Urba, Walter, et al.
Publicado: (2015)

Pragmatic dose-escalation methods incorporating relative dose intensity assessment for molecularly targeted agents in phase I trials
por: Hirakawa, Akihiro, et al.
Publicado: (2019)

A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer
por: Baughman, Jan, et al.
Publicado: (2015)

A dose-escalation clinical trial to evaluate the safety and immunogenicity of a replication-defective HIV-1 vaccine-HIVAX
por: Tung, F, et al.
Publicado: (2012)

Comparison of great artery dimensions in 3-D dual-phase SSFP, compared with 3D CE-MRA and phase-contrast imaging (magnitude image)
por: Sun, Aimin, et al.
Publicado: (2015)

P1463: PHASE I DOSE ESCALATION OF LAVA-051, A NOVEL BISPECIFIC GAMMA-DELTA T-CELL ENGAGER (GAMMABODY™), IN RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES
por: Broijl, A., et al.
Publicado: (2022)

A pragmatic approach to the design and calibration of a Bayesian CRM dose finding trial
por: Cole, Michael, et al.
Publicado: (2015)

Improving congenital heart disease imaging using 3d whole-heart dual-phase MRI
por: Hussain, Tarique, et al.
Publicado: (2011)

Maximum penalized likelihood estimation of interspike interval distribution
por: Pokora, Ondrej, et al.
Publicado: (2013)

De-escalation practice pattern in an Indian intensive care unit
por: Bhakta, A, et al.
Publicado: (2010)

Assessment of energy loss in aortic stenosis using Bayesian multipoint phase-contrast MRI
por: Binter, Christian, et al.
Publicado: (2013)

Toxicity‐dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials
por: Wheeler, Graham M., et al.
Publicado: (2017)

Bayesian optimization for estimating the maximum tolerated dose in Phase I clinical trials
por: Takahashi, Ami, et al.
Publicado: (2021)

Phase I single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of BMS-927711 in healthy subjects
por: Tong, G, et al.
Publicado: (2013)

Antibiotic costs in bacteremic and nonbacteremic patients treated with the de-escalation approach
por: Evodia, E, et al.
Publicado: (2008)

De-escalation of empiric antibiotic therapy in sepsis - an indian observational study
por: Jakkinaboina, S, et al.
Publicado: (2015)

A Bayesian dose-finding procedure applied to a seamless phase I/II trial in rheumatoid arthritis
por: Whitehead, Anne, et al.
Publicado: (2011)

Phase I Dose-Escalation Study of Nimustine in Tumor-Bearing Dogs
por: TAKAHASHI, Masashi, et al.
Publicado: (2014)

Phase I dose-escalation oncology trials with sequential multiple schedules
por: Günhan, Burak Kürsad, et al.
Publicado: (2021)

Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results
por: Kefford, Richard, et al.
Publicado: (2014)

P1005: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF SELINEXOR PLUS RUXOLITINIB IN PATIENTS WITH TREATMENT-NAÏVE MYELOFIBROSIS
por: Ali, H., et al.
Publicado: (2022)

Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients
por: Pandha, Hardev, et al.
Publicado: (2015)

De-escalation of antimicrobial therapy in Gram-negative sepsis: easier said than done?
por: Phee, L, et al.
Publicado: (2011)

De-escalation therapy: 1-year experience in a general intensive care unit
por: Gyurov, E, et al.
Publicado: (2005)

Forecasting escalation of cardio-respiratory instability using noninvasive vital sign monitoring data
por: Guillame-Bert, M, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_g0j08jepg232jho58pgh2vsoen